Key result
FDA REMS for prasugrel lacks adequate quality and impact for post-approval safety activities.
Answers are grounded in this paper and cite their sources.
The evaluation of the prasugrel REMS highlights the need to improve the quality and impact of FDA post-approval activities to maximize drug safety.
The prasugrel REMS consisted of passive educational materials whose adequacy was evaluated using highly limited, one-time, cross-sectional surveys. Our assessment adds to evidence suggesting the importance of improving the quality and impact of the FDA's post-approval activities to maximize drug safety.
No takes yet. Share an insight, caveat, or question.
Metkus et al. (2024) studied this question. The assessment indicates that the FDA's REMS for prasugrel is inadequate in quality and impact, suggesting a need for improvement in post-approval safety activities.
Synapse has enriched 10 related papers. Consider them for comparative context: